Featured News

As a result of our work, we are pleased to announce that the Celiac Disease Foundation will host an Ask-the-FDA Educational Webinar on October 13, 2022.

Accelerating research for treatments and a cure for celiac disease is the top priority of the Celiac Disease Foundation.  We are optimistic that the current surge of research will produce the first FDA-approved treatment for celiac disease. Our optimism comes from the variety of approaches biopharmaceutical companies are taking to treat the disease to make it…

With the 9 Meters decision to halt the CedLara Phase 3 trial because of the cost of patient recruitment, it is more imperative than ever that our celiac community comes together to enroll in clinical trials. The Celiac Disease Foundation has been demanding treatments primarily because up to 50% of all celiac patients report ongoing symptoms even when attempting…

The Celiac Disease Foundation is pleased to announce the establishment of two international celiac disease research prizes to inspire a new generation of researchers whose work in celiac disease will be invaluable.

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).

On April 8 and April 9, the Celiac Disease Foundation is sponsoring the Columbia University Celiac Disease Center International Symposium on Celiac Disease.

To share with you some insight into our advocacy work, I recently interviewed Mark Van de Water, Senior Advisor at Baker Donelson.

A few highlights from research studies published in peer-reviewed journals in the last few months are products of the research grants CDF awarded.

For the first time ever, the NIH has released a Notice of Special Interest to provide dedicated research funding for the study of celiac disease.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.